Zack's Merger benefits include the enhanced scientific, technical and operational expertise that comes from combining the research teams and cost reductions from the elimination of duplicative salaries, administrative, regulatory and other public company expenses. Some of the primary benefits of the merger include:
Synergies from xB3 platform for use in Midatech’s lead program in DIPG
o Improved delivery via the SynchroMed II Pump
o Opportunity for new chemical entity and additional IP protection when employing xB3
Reduction in duplicative general and administrative expenses
Improved capital raising abilities with NASDAQ listing
Elimination of Lind debt from Bioasis’ balance sheet
Corporatewide focus on rare disease
o Enables small, cost-effective clinical trials
o Eligible for fast-track designation and early approval
Expanded experience and breadth of research and development team
BIOAF: Merger with Midatech Pharma (yahoo.com)